Muscleblind-like protein 1 nuclear sequestration is a molecular pathology marker of DM1 and DM2.
about
Studying a Drug-like, RNA-Focused Small Molecule Library Identifies Compounds That Inhibit RNA Toxicity in Myotonic DystrophyExpanded CCUG repeat RNA expression in Drosophila heart and muscle trigger Myotonic Dystrophy type 1-like phenotypes and activate autophagocytosis genes.Immortalized human myotonic dystrophy muscle cell lines to assess therapeutic compounds.Pre-mRNA processing is partially impaired in satellite cell nuclei from aged muscles.Rationally designed small molecules targeting the RNA that causes myotonic dystrophy type 1 are potently bioactive.Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules.Features of modularly assembled compounds that impart bioactivity against an RNA target.Triplet repeat RNA structure and its role as pathogenic agent and therapeutic targetRNA-binding protein misregulation in microsatellite expansion disordersIncreased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylationRational design of bioactive, modularly assembled aminoglycosides targeting the RNA that causes myotonic dystrophy type 1.Cellular toxicity of expanded RNA repeats: focus on RNA foci.Skeletal muscle features in myotonic dystrophy and sarcopenia: do similar nuclear mechanisms lead to skeletal muscle wasting?Clinical aspects, molecular pathomechanisms and management of myotonic dystrophies.RNA Transcription and Maturation in Skeletal Muscle Cells are Similarly Impaired in Myotonic Dystrophy and Sarcopenia: The Ultrastructural Evidence.Routinely frozen biopsies of human skeletal muscle are suitable for morphological and immunocytochemical analyses at transmission electron microscopyHistochemistry through the years, browsing a long-established journal: novelties in traditional subjects.Structural and functional alterations of the cell nucleus in skeletal muscle wasting: the evidence in situ.Cultured myoblasts from patients affected by myotonic dystrophy type 2 exhibit senescence-related features: ultrastructural evidence.Myotonic Dystrophy Type 2: An Update on Clinical Aspects, Genetic and Pathomolecular Mechanism.HTS-Compatible Patient-Derived Cell-Based Assay to Identify Small Molecule Modulators of Aberrant Splicing in Myotonic Dystrophy Type 1.Phenylbutazone induces expression of MBNL1 and suppresses formation of MBNL1-CUG RNA foci in a mouse model of myotonic dystrophy.Molecular Effects of the CTG Repeats in Mutant Dystrophia Myotonica Protein Kinase Gene.Muscleblind-like1 undergoes ectopic relocation in the nuclei of skeletal muscles in myotonic dystrophy and sarcopenia.Mouse model of muscleblind-like 1 overexpression: skeletal muscle effects and therapeutic promise.Altered levels of the splicing factor muscleblind modifies cerebral cortical function in mouse models of myotonic dystrophy.RNA/MBNL1-containing foci in myoblast nuclei from patients affected by myotonic dystrophy type 2: an immunocytochemical study
P2860
Q28830592-02A2D296-6B09-4396-9EA5-C8F99D5F0153Q30854929-9882466A-FB88-4F10-ACEE-8497AF2FC1C3Q33588075-4E64FF6B-AFD6-4F43-B9FB-20F5B98862C9Q33861160-ACA79E08-A2F8-47E5-ADDA-83366492D01EQ34158462-B80D4FED-D411-4817-8021-9DCDAE8013E8Q34786164-BCDC30B1-2114-4CAA-9AB3-7B1629C15A2BQ34986416-4FAEC1EB-4B4D-4963-A4CB-762A0935E509Q35633648-93D4CC59-B431-438B-918A-6E5F2464F94DQ35789502-58AEDC23-7942-4B2D-9306-98C02A2844D6Q36154872-B4C0AFB8-5F47-400F-BD41-52EB8B77B388Q36484500-6FCAFF17-9F4E-4D79-83E9-27F3C836D31EQ37897768-CFCC690F-DCA5-4E27-A828-50C76D890027Q38048633-13BA014C-914E-434A-933C-F695A777B848Q38209927-FCAD26D6-06E5-4A5C-A93D-ACF29AF0FB09Q38240142-E67683DA-E61D-4E28-9913-1A2D75754433Q38313385-2FC25677-78AB-4E16-BF97-12EAC6BCFBD7Q38313475-D937814D-4AF1-4746-8091-793F3543D9A8Q38313536-A288A441-8071-40BA-A820-BDFCE188BCDBQ38852912-052A8585-22A8-4A4A-8335-DD0A060F4696Q39012035-74C724C4-D716-4849-8842-334A6D0C2E31Q39700299-ADA75C32-BA51-4782-A930-9E43E5951F8CQ40794185-23397231-1564-4497-862D-891A5310552BQ41560194-5B475792-99ED-4EA8-BE42-1CD57AA15806Q41975388-7FE05B29-3AF9-4BA0-AF72-EEB81D094E4FQ42235812-24F5B975-9CAD-4441-9632-42F49229678BQ50056107-49F311D8-F985-4249-B16B-9025F2ADE8D1Q57085801-097A03A9-DF13-42EA-BD85-4951204F68D9
P2860
Muscleblind-like protein 1 nuclear sequestration is a molecular pathology marker of DM1 and DM2.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Muscleblind-like protein 1 nuc ...... thology marker of DM1 and DM2.
@ast
Muscleblind-like protein 1 nuc ...... thology marker of DM1 and DM2.
@en
Muscleblind-like protein 1 nuc ...... thology marker of DM1 and DM2.
@nl
type
label
Muscleblind-like protein 1 nuc ...... thology marker of DM1 and DM2.
@ast
Muscleblind-like protein 1 nuc ...... thology marker of DM1 and DM2.
@en
Muscleblind-like protein 1 nuc ...... thology marker of DM1 and DM2.
@nl
prefLabel
Muscleblind-like protein 1 nuc ...... thology marker of DM1 and DM2.
@ast
Muscleblind-like protein 1 nuc ...... thology marker of DM1 and DM2.
@en
Muscleblind-like protein 1 nuc ...... thology marker of DM1 and DM2.
@nl
P2093
P1476
Muscleblind-like protein 1 nuc ...... thology marker of DM1 and DM2.
@en
P2093
P304
P577
2006-07-01T00:00:00Z